Acute myocardial infarction. Subsequent ST elevation (STEMI) myocardial infarction of unspecified site
Conditions
Interventions
Intervention 1: Intervention group: Medical intervention with EMPAGLIFLOZIN KHARAZMI 10 MG Tablet per day (single dose) for 3-5 days. Intervention 2: Control group: The patients in the placebo group w
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Diagnosis of ST elevation MI acute myocardial infarction by a cardiologist based on clinical variables and ECG Glomerular filtration rate (rGFR) more than 30 Systolic blood pressure before the first dose of the drug more than 110 Diastolic blood pressure before the first dose of medicine more than 70 The first dose of drug administration less than 72 hours after the occurrence of an acute stroke
Exclusion criteria
Exclusion criteria: People with diabetes other than type 2 History of diabetic ketoacidosis Hemodynamic instability caused by intravenous administration of catecholamine, calcium sensitizers, or phosphodiesterase inhibitors Acute symptomatic urinary tract infection Genital infection Continuous treatment with SGLT2 inhibitors Being treated with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin) four weeks before the screening visit. Known allergy to SGLT-2 inhibitors Severe hypoglycemia in the last six months treated with insulin or sulfonylurea Symptomatic acute urinary tract infection (UTI) or genital infection Patients currently receiving treatment with any SGLT-2 inhibitor (dapagliflozin, canagliflozin, empagliflozin).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiovascular function in echocardiography. Timepoint: The systolic and diastolic function of the left ventricle of the heart is measured in two stages (before the intervention and then 4 to 6 weeks after discharge from the hospital). Method of measurement: Using an echocardiography device using the Simpson method.;Quality of life with SF36 questioner. Timepoint: Before and after interventions. Method of measurement: SF36 questioner. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Shaghaghi
Hamedan University of Medical Sciences
Outcome results
None listed